Zobrazeno 1 - 10
of 73
pro vyhledávání: '"N, Kadima"'
Autor:
John M. Tumbo, Faustin N. Kadima
Publikováno v:
African Journal of Primary Health Care & Family Medicine, Vol 5, Iss 1, Pp e1-e5 (2013)
Background: The prevalence of diabetes mellitus (DM) is increasing worldwide, with more than 90% being type 2. In South Africa, DM is common amongst all racial groups with the highest prevalence amongst the Indian population (15.8%), followed by the
Externí odkaz:
https://doaj.org/article/46f0ae580561465abef6aaea84cb29fe
Autor:
Kabemba, N. Kadima1 nazaire.kadima@upn.ac.cd, Gikug, J. Munganga1, Otono, F. Bulubulu1, Hity, S. N. D. Mutambel'1
Publikováno v:
Tropicultura. oct-dec2017, Vol. 35 Issue 4, p173-179. 7p.
Autor:
E A Tembe-Fokunang, L. N. Njinkio, J. Ngoupayo, C. N. Fokunang, J. N. Kadima, B. T. Ngadjui, F. A. Kechia, B. Ngameni, F. K. Mushagalusa, B. Atogho-Tiedeu, W. F. Mbacham
Publikováno v:
Journal of Pharmacognosy and Phytotherapy. 9:123-130
This is a phytochemical and zootechnical study on Physalis peruviana leaves in streptozotocin induced diabetic rats. This was part of a scientific development program of plant resources used in Congolese traditional medicine for the treatment of diab
Publikováno v:
European Journal of Medicinal Plants. 12:1-13
Autor:
Andre N. Kadima, Marina Demcheva, David J. Cole, William E. Gillanders, Christophe L. Nguyen, Mark P. Rubinstein, Mohamed L. Salem, Yuehua Zhou, John N. Vournakis
Publikováno v:
The Journal of Immunology. 172:5159-5167
Interleukin-12 can act as a potent adjuvant for T cell vaccines, but its clinical use is limited by toxicity. Paracrine administration of IL-12 could significantly enhance the response to such vaccines without the toxicity associated with systemic ad
Autor:
Mohamed L. Salem, David J. Cole, Andre N. Kadima, William E. Gillanders, Michael I. Nishimura, Mark P. Rubinstein, Christophe L. Nguyen
Publikováno v:
The Journal of Immunology. 170:1209-1217
The adoptive transfer of tumor-specific T cells expanded in vitro can be of significant therapeutic value in select cancer patients. This strategy is limited though, as it is often difficult, if not impossible, to obtain T cells of clinical value. Th
Autor:
Christophe L. Nguyen, Andre N. Kadima, Mohamed L. Salem, Mark P. Rubinstein, Michael I. Nishimura, William E. Gillanders, David J. Cole
Publikováno v:
Cancer gene therapy. 16(2)
Adoptive T-cell therapy is clinically efficacious in the treatment of select cancers. However, it is often difficult to obtain adequate numbers of tumor-specific T cells for therapy. One method for overcoming this limitation is to generate tumor-spec
Autor:
Yian Chen, Mohamed L. Salem, Andre N. Kadima, Sabry A. El-Naggar, David J. Cole, William E. Gillanders, Mark P. Rubinstein
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 30(1)
Although cyclophosphamide (CTX) has been clearly shown to enhance active specific and adoptive immunotherapies, the mechanism(s) underlying these beneficial effects have not been clearly defined. To define the impact of CTX preconditioning on the ant
Autor:
Mohamed L. Salem, David J. Cole, John N. Vournakis, William E. Gillanders, Sabry A. El-Naggar, Mark P. Rubinstein, Andre N. Kadima, Marina Demcheva
Publikováno v:
Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 26(9)
It has become increasingly apparent that the ability to generate an optimal host immune response requires effective cross talk between the innate and adaptive components of the immune system. Pro-inflammatory cytokines, in particular those that can i
Publikováno v:
Vaccine. 24(24)
Poly (I:C), a TLR3 ligand, has shown promise as a vaccine adjuvant to CD8(+) T cell responses. The underlying mechanisms involved in creating this adjuvant response in vivo, however, have not been well defined. In this study, we explored the contribu